Podcasts about comart

Today, hosts Michael and Josh are joined by the wonderful Dr James McCracken to discuss highlights from ASCO 2025 in the areas of upper GI and hepatobiliary cancer. This episode focuses on two items that are (as Michael repetitively insists) "big ticket": MATTERHORN and Destiny-Gastric04. In addition, James gives his thoughts on studies that look at immunotherapy and novel neoadjuvant chemotherapy in pancreatic cancer, and a small study examining a perioperative approach to resectable biliary tract cancer.Studies discussed in the episode:MATTERHORNDestiny-Gastric04NeoIMPACTCASSANDRAGAINFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Today, we discuss the latest advancements in gynecological oncology presented at ASCO 2025, featuring insights from Dr. Prachi Bhave. The conversation covers significant trials including the TRUST trial on ovarian cancer surgery timing, the Rosella trial for platinum-resistant ovarian cancer, the FIRST study on immunotherapy in advanced ovarian cancer, and the update on the Keynote A18 trial for cervical cancer. The discussion emphasizes the importance of these studies in shaping future treatment strategies and improving patient outcomes.Studies discussed in the episode:Trust studyFIRST/ENGOT-OV44Rosella study (GOG-3073, ENGOT-ov72)Keynote A18For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Heather, Nick and Matt go back to their old ways and experience the $10 Nintendo Switch 2 user manual/museum Nintendo Switch 2 Welcome Tour. Check out our brand new merch at kinshipgoods.com/getplayedFollow us on social media @getplayedpodMusic by Ben Prunty benpruntymusic.comArt by Duck Brigade duckbrigade.com For ad-free main feed episodes, our complete back catalogue including How Did This Get Played? and our Premium DLC episodes and our exclusive show Get Anime'd where we're currently watching Gurren Lagann go to patreon.com/getplayed Join us on our Discord server here: https://discord.gg/getplayed Wanna leave us a voicemail? Call 616-2-PLAYED (616-275-2933) or write us an email at getplayedpod@gmail.com Advertise on Get Played via Gumball.fm All of our links can be found at linktree.com/getplayedpodSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode, Dr. Janet Abrahm shares transformative insights from ASCO 2025, focusing on palliative care and supportive care in oncology. Topics discussed include the role of exercise in cancer survival, cannabis use for symptom management, and the challenges of chemotherapy-induced peripheral neuropathy. We also highlight the importance of communication with patients, particularly in the context of grief and transition to palliative care, as well as the pervasive issue of burnout among oncology professionals.Studies discussed in the episode:Cannabis [Educational session re: ASCO 2024 Guideline; abstrs 120831; 12061]Hot flashes [508]Is local estrogen therapy safe for breast cancer survivors [578]Duloxetine: Disappointing results [12010]2021 study report [9005] with discussion of 2023 updatesChallenge Trial - Exercise extends life in Colon CA pts: already in NEJM and reported earlier in ASCO GI meeting LBA3510AND MORE!Check out Janet's page for more palliative care information: https://janetabrahm.com/ For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

In this episode, Dr. Ned McNamee discusses the latest advancements in lung cancer treatment presented at ASCO 2025, focusing on significant studies such as the Phase 3 DeLLphi-304 study and Checkmate 816. They explore the implications of these findings for clinical practice, including the challenges of managing immune-related side effects and the potential for neoadjuvant immunotherapy to improve patient outcomes. The conversation also touches on the economics of oncology and the surprising results regarding the timing of immunotherapy administration.Studies discussed in the episode:Phase 3 DeLLphi-304NeoADAURACheckmate816IMFORTE studyRandomized trial of relevance of time-of-day of immunochemotherapy for progression-free and overall survival in patients with non-small cell lung cancer.AND MORE!For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Send us a textThis week, Wes and Todd sit down with Painter & Illustrator, Kevin Johnson. Kevin discusses his early engagement with art, comic books, Louisville, teaching himself to draw, favorite comic book artists, school, keeping it fresh, the Army, creating and drawing during his time in the service, his journey after retiring from the Army, Comic Con, Full Sail University, the Colorado Springs art scene, Black Lion, taking time serious, graphic design, animation, Craigslist, reinventing yourself, Thomas Blackshear and mentorship, butterflies, imagination, mixed media, growing as an artist, his pencil & charcoal series, Black Art in America, the Solidarity Mobile Mural Project, social media, Flaten Art Museum, his current shows, routine, clouds, critiques, collectors, Rogue Gallery, pricing, and his advice to young artists.Join us for an inspirational conversation with Kevin Johnson!Check out Kevins' website at www.kevjart.comFollow Kevin on social media:Instagram - www.instagram.com/kevjart - @kevjartFacebook - www.facebook.com/KevJArt/ See Kevin's art in person at these galleries: The Vault Gallery in The Mining Exchange Hotel - www.miningexchangehotel.comExhibit runs from June 1st – August 25th, 2025 Auric Gallery - www.auricgallery.com Broadmoor Galleries - www.broadmoorgalleries.com A.R Mitchell Museum of Western Art - www.armitchellmuseum.com Black Art In America - www.blackartinamerica.comArt on tour from Illinois to D.C. “Change That Narrative” on display at the Illinois State Capitol building in Springfield, Illinois.Follow us on Instagram: @tenetpodcast - www.instagram.com/tenetpodcast/ @wesbrn - www.instagram.com/wesbrn/ @toddpiersonphotography - www.instagram.com/toddpiersonphotography/ Follow us on Facebook: www.facebook.com/TenetPodcast/ Email us at todd@toddpierson.com If you enjoyed this episode or any of our previous episodes, please consider taking a moment and leaving us a review on your favorite podcast platform. Thanks for listening!

Today, we cover ASCO 2025 in the genitourinary space, specifically bladder and renal cancer. Dr. Enrique Grande, a renowned oncologist and Program and Clinical Research lead of MD Anderson Cancer Centre, Madrid, joins us. This is a mega episode where we cover AMPLITUDE, JAVELIN MEDLEY, CHECKMATE 901 and NIAGARA, advancing urothelial cancer care; SEAR 02 and the CReST trial, pushing boundaries in bladder cancer; CHECKMATE 214; LITESPARK-005 and LITESPARK-004, showcasing belzutifan's promise; and KEYNOTE-564, adjuvant therapy for kidney cancer. Stay tuned for an insightful conversation on how these trials may be transforming patient outcomes!Studies discussed in the episode:CHECKMATE 901NIAGARACHECKMATE 214CREST trialSEAR 02LITESPARK 004/005AMPLITUDEJAVELIN MEDLEYFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Today, we're joined by Professor Anthony Joshua, head of Medical Oncology at St. Vincent's Hospital, Sydney, and a global leader in prostate cancer and melanoma. In this episode, Professor Joshua discusses multiple trials including AMPLITUDE, advancing prostate cancer therapies; CAN 2409, exploring immunotherapy; ARANOTE, showing darolutamide's impact on progression-free survival; the prognostic significance of PSA 0.2; and the landmark STAMPEDE study. Join us for a deep dive into these game-changing studies. Let's begin! It's a jam-packed episode!Studies discussed in the episode:AMPLITUDECAN2409ARANOTESTAMPEDE*AND MORE!For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

In this episode, we unpack game-changing insights from ASCO 2025 with a spotlight on breast cancer. Joining us is Dr. Adam Brufsky, a trailblazing oncologist and professor at the University of Pittsburgh, with 30 years of experience, whose expertise has helped shape the direction of treatment. Trials discussed include the SERENA-6 trial, which examines camizestrant plus CDK4/6 inhibitors in HR-positive, ESR1 mutation breast cancer; the DESTINY-Breast09 trial, highlighting trastuzumab deruxtecan in combination with pertuzumab; and the INAVO120 trial, revealing inavolisib's triplet therapy response in PIK3CA-mutated, HR-positive, HER2-negative disease. Join us for a deep dive into these game-changing findings and their impact on patient care.Studies discussed in the episode:SERENA-6DESTINY BREAST 09INAVO 120For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

In our second plenary episode, we're spotlighting two pivotal phase 3 trials: SERENA-6, which explores ctDNA-guided treatment with camizestrant to delay progression in HR-positive, HER2-negative advanced breast cancer with ESR1 mutations, and NIVOPOSTOP, a landmark study showing improved disease-free survival with adjuvant nivolumab in high-risk, resected head and neck squamous cell carcinoma. Join us as we unpack these practice-changing findings with expert insight and a couple of dad jokes along the way.Studies discussed in the episode:SERENA-6NIVOPOSTOPFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

This year, Michael and Josh bring you the American Society of Clinical Oncology (ASCO) 2025. To keep it fresh, we're doing things a little differently, but rest assured, we'll bring along a global host of experts to deliver the very best from the practice-changing, thought-provoking, design-defining trials you know and love from this podcast.This episode focuses on adjuvant atezolizumab in the colon cancer space and the use of perioperative durvalumab in the gastric cancer space. Both are exciting spaces and have the potential to be practice-changing.Don't forget to like and subscribe if you love what we do!Studies discussed in the episode:ATOMICMATTERHORNFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

This week, we talk about metastatic bladder cancer. The last two years have seen drastic changes in this space, with the addition of immunotherapy and ADCs in a first-line setting. While exceptionally effective, toxicity and patient selection remain challenging. The other big issue with what's best for the second line? That's the golden question.Studies discussed in the episode:EV-302THORFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

This week, we explore muscle-invasive bladder cancer (MIBC). This space has made significant progress with the completion of two pivotal trials. The first was VESPER, comparing two chemotherapy regimens. The key to this trial may be the amount of cisplatin delivered, but there are some unknowns in a real-world setting. It also compared the neoadjuvant to the perioperative space. The second trial utilises immunotherapy in the perioperative landscape and is the first trial to so but only used one chemotherapy regimen.A must-listen to episode comparing the complexities of early bladder cancer and the options available.Studies discussed in the episode:VESPERNIAGARAFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

As we "EMBARK" on our next Prostate Cancer adventure via the "SOLAR" system to "SATURN," Michael and Josh explore the idea of biochemical recurrence in prostate cancer and the role of radiotherapy in tumour-directed therapy for de novo versus recurrent PSMA PET–defined oligo-M1 prostate cancer. Both excellent studies raise the question of newer technologies and how we apply this information to trials that already exist.Studies discussed in the episode:EMBARKSOLAR/SATURNFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

To celebrate Global Accessibility Awareness Day, Mikaela and Paul recorded a special episode live at ARCtic Conference in Oulu, Finland, with a distinguished panel of accessibility champions: Rob Whitaker, Daniel Devesa Derksen-Staats and Klemens Strasse.If accessibility seems like an overwhelming subject, don't panic; we show you not just why but also give you tips on how to get started with ensuring your apps are as accessible as possible — and remember the mantra, ‘progress over perfection'!Essential links from the episode:Global Accessibility Awareness Day: https://accessibility.dayARCtic Conference: https://arcticonference.comArt of Fauna by Klemens Strasser: https://apps.apple.com/gb/app/art-of-fauna-cozy-puzzles/id1630468596The practice of inclusive design, by Linda Dong: https://developer.apple.com/videos/play/wwdc2021/10275/Art of Fauna by Klemklem Strasser: https://apps.apple.com/gb/app/art-of-fauna-cozy-puzzles/id1630468596Sim Daltonism: https://apps.apple.com/gb/app/sim-daltonism/id1050503579Art of Fauna by the World's Biggest Mandarin Duck Fan: https://apps.apple.com/gb/app/art-of-fauna-cozy-puzzles/id1630468596Conferences:SwiftCraft (19–21 May): https://swiftcraft.ukConference organisers: we'd love to feature more events here on a regular basis. Get in touch with us when early bird tickets go on sale, or when you announce speakers or something else, and we'll do our best to feature you!

Marie Curie's life work laid the foundations for theranostics. This week, we talk about Lutetium, a rare earth metal, and its role in Prostate Cancer. Lutetium-177 PSMA therapy is a radiation therapy that targets prostate cancer. It is used in the advanced, metastatic, and castrate-resistant space. Lutetium is bound to a protein called PSMA. PSMA is overexpressed in many prostate cancers and can be used to target these cancer cells via the membrane antigen.Studies discussed in the episode:UpFrontPSMAVISION trial (and a bit on TheraP)For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Prostate Cancer has a multitude of presentations, but when metastatic, it usually spreads directly to the lymph nodes or the bones. This episode focuses on the contentious definition of "M0 Castrate Resistant Prostate Cancer (CRPC)", also known as Nonmetastatic CRPC. Does this definition exist, and what role will PSMA PET have in this cohort of patients? The second trial, TITAN looks at apalutamide, another ARPI/ARSI and how it compares to it's cousins who are fighting for the top spot in the prostate cancer world.Studies discussed in the episode:ARAMISTITANFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Jeremy and Dan sit down for a fun conversation about the importance of finding your people in comedy. They dig into Jeremy's surprising path from life as a preacher to chasing laughs onstage. Plus, they swap some unforgettable stories — including a New Year's Eve show that went completely off the rails.Jeremy AlderHomeschooled in the heart of Texas by fundamentalist missionary parents with apenchant for conspiracy theories, Jeremy's childhood was anything but conventional.Steeped in a world of alternative facts and fervent beliefs, he learned early on to findthe humor in life's absurdities.Now married with children of his own, Jeremy's material delves into the trials andtribulations of growing up homeschooled, the complications of religion, the mysteriesof marriage, the chaos of parenting, and the existential crisis of aging—all with ahealthy dose of skepticism and silliness, dry wit and charm.https://www.jeremyalder.comArt of Bombing:"Nobody Had a Podcast Called The Art of Bombing" Theme by John Hult https://johnhult.bandcamp.com/album/half-a-life-to-recoverBumpers provided by https://www.facebook.com/joenicolamusic Website: https://www.artofbombingpod.com/ Links: https://linktr.ee/artofbombingpodHosts:Dan Bublitz Jr: http://www.danbublitz.com/ Larry Smith: https://larrysmithcomedy.com/Become a supporter of this podcast: https://www.spreaker.com/podcast/the-art-of-bombing-a-comedy-podcast--5788059/support.

This week, we interview Dr. Cristofanilli, a globally recognised expert in inflammatory breast cancer research and precision medicine. With decades of clinical experience and groundbreaking contributions to translational research, he has transformed the way we approach metastatic breast cancer, leading advances in liquid biopsy, molecular profiling, and targeted therapies.Dr Cristofanilli serves as the Director of Breast Medical Oncology, Associated Director of Precision Oncology at the Meyer Cancer Centre, and co-leader of the MCC Breast Cancer Disease Management team, in addition to being the Scientific Director of the Englander Institute of Precision Medicine.For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Warning! This episode is filled with murder, mystery, and mommy issues. Join us as we discuss Alfred Hitchcock's 1960 slasher classic, ‘Psycho.'Brought to you by your hosts, Ruth and DP.Please support us by following us on any (preferably all) of our social media platforms. It really means the world to us!Instagram:https://www.instagram.com/didyougetthatonfilm/Facebook:https://www.facebook.com/didyougetthatonfilm/Youtube:https://www.youtube.com/@DidYouGetThatOnFilmWebsite:https://didyougetthatonfilm.buzzsprout.comArt by Sebastian Westbrook (@Spwestbrookart on Instagram and Facebook)

Bailey started with public speaking, but the desire to do standup had always been there. She and Dan discuss the community that is standup, connecting to an audience through humor, the comedic delight that weird small towns can be, festivals, submission tapes, and how inexperience and a venue can affect you.Bailey PopeBailey Pope (She/Her/Etc) is a New York-based Comedian, writer, and pigeon-holed actress, providing the overly-tattooed, failed rock star transgender woman comedy that everyone has been searching centuries for. Bailey has been featured in festivals including the New York Comedy Fest, Limestone, Lookout, and more. She has also shared stages with Roy Wood Jr. Maria Bamford and Sam Jay. As an actress, she often appears as “Angry bartender” or “Aloof tattoo artist” in shows such as AppleTV+ “City On Fire”. Her writing has been published by Hard Times and Refinery29.https://www.baileypopecomedy.comArt of Bombing:"Nobody Had a Podcast Called The Art of Bombing" Theme by John Hult https://johnhult.bandcamp.com/album/half-a-life-to-recoverBumpers provided by https://www.facebook.com/joenicolamusic Website: https://www.artofbombingpod.com/ Links: https://linktr.ee/artofbombingpodHosts:Dan Bublitz Jr: http://www.danbublitz.com/ Larry Smith: https://larrysmithcomedy.com/Become a supporter of this podcast: https://www.spreaker.com/podcast/the-art-of-bombing-a-comedy-podcast--5788059/support.

Hey Guys! We hope you enjoy this new episode of DYGTOF- Pulse Check. This week, we are discussing upcoming releases/ remakes, IKWYDLS, Academy Awards outcomes and unfortunately, more Scream 7 casting announcements.Pulse Checks won't be our typical movie reviews, but instead us freely discussing various horror topics including our interests, recent events, updates and announcements. But don't worry, these will not be replacing our movie reviews, we have plenty of those coming soon! Brought to you by your hosts, Ruth and DP.You can follow DP and find all of his movie ratings on his letterbox: https://letterboxd.com/maybetomorrow/Please support us by following us on any (preferably all) of our social media platforms. It really means the world to us!Instagram: https://www.instagram.com/didyougetthatonfilm/ Facebook: https://www.facebook.com/didyougetthatonfilm/ Youtube: https://www.youtube.com/@DidYouGetThatOnFilm Website: https://didyougetthatonfilm.buzzsprout.comArt by Sebastian Westbrook (@Spwestbrookart on Instagram and Facebook)

Today, we discuss the role of triplet therapy (ie, chemotherapy and androgen receptor signalling inhibitor and ADT) in high-volume metastatic hormone-sensitive prostate cancer and whether darolutamide is equivalent to the other androgen receptor signalling inhibitors in the castrate-sensitive space. Two good trials, and as always, some interesting discussion points.Studies discussed in the episode:ARASENSARANOTEFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Send us a textHow are you this week? Have you been seeing more places, spaces, where two opposing forces or states of being intersect? Have you witnessed the magic in those juicy spaces? If you're nodding yes, has the supernatural winked at you? Given you more overt breadcrumbs? This morning as I ran, I watched the clouds move across the sky, one in particular was shaped like a pyramid. It then morphed into a shark. Is cloud scrying a thing? Certain shapes, designs, patterns, images evoke a deep knowing in me, remind me of my connection to everything else. A spiral, for example. It calls to mind a whirlpool, a vortex of energy, a portal. Spirals, pyramids, waves, checkerboard patterns, art on a cave wall, the handprint of another human created thousands of years ago that we can picture placing a hand over, a mental link to ancient ones that stretches the bounds of time and space. Art is a magical bridge, both from us to other civilizations, or cultures, or individuals. It's also an internal bridge between sides of our brain, logic and creativity, math and mental health. Our self-expression is potent medicine.Let's get into it. What to Read/Listen/Watch NEXTWhat Art Does to Your Brain, Berkeley.eduYour Brain on Art, Susan Magsamen and Ivy Ross, Amazon.comArt and the Brain, The Healing Power of ArtHow to Integrate Art into Your Daily Life, The Roanoke Star dot comWhat Your Favorite Color Says about You, According to an Expert, The Pioneer Woman Have you tried the GoodPods app yet? It's free and a fun way to share podcasts with friends and family! Curious Cat Podcast is there, and is sitting pretty in the Top 5 of Angels and other categories! Be one of the first to share and recommend podcasts to your friends. Curious Cat Crew on Socials:Curious Cat on Twitter (X)Curious Cat on InstagramCurious Cat on TikTokArt Director, Nora, has a handmade, ethically-sourced jewelry company!

The rise and rise of Androgen Receptor Pathway (or Signalling) Inhibitors has changed the world of metastatic prostate cancer forever. What was once a cancer with a finite number of treatment options has flourished into a chasm of therapies, many more effective and less toxic than their therapeutic grandparents.Studies discussed in the episode:ARCHESENZAMETFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Our final breast cancer episode is here! Today, we are talking about the role of Gene Expression Assays in early hormone receptor-positive breast cancer management. The specific questions we asked included when we can de-escalate and for which cohort of patients these assays can be used. There's lots more to this episode, but we explore the role of Oncotype Dx!Studies discussed in the episode:TAILORxRxPonderFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

This week, we prematurely dive into prostate cancer (one breast episode remaining - whoops!), where we explore the early pivotal trials, including the role of abiraterone in metastatic hormone-sensitive prostate cancer and the use of docetaxel in high and low-volume prostate cancer.Studies discussed in the episode:LATITUDESTAMPEDEFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

As our breast cancer journey comes close to finishing, it was always the destiny of your cohost's on Oncology for the Inquisitive Mind to talk about HER2-positive breast cancer. This week, we target both antibody-drug conjugate therapy and targeted therapy (trastuzumab deruxtecan and pertuzumab). While HER2-positive cancer's survival is one of the best for metastatic disease, this was not always the case. Studies discussed in the episode:DESTINY 03 CLEOPATRA TrialFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Send us a textOriginally released in September of 2021, this episode has been enhanced with additional music and sound effects.Sixteen years before Al Capone came to Chicago and long before anyone could blame violence on video games, three boys just out of their teens became robbers and worse in Chicago with brazen acts of thievery and wanton killings. Today we're discussing the Automatic Trio and the Car Barn Murders.Want to help support the show? Buy me a coffee!https://www.buymeacoffee.com/chicagohistoryNeed music for YOUR projects? Audiio has got you covered. Try a free trial here:https://audiio.com/pricing?oid=1&affid=481Amazon Affiliate Links (anything you buy - not just this stuff - through these links helps benefit the show):The Gangs of Chicago: An Informal History of the Underworld by Herbert Asburyhttps://amzn.to/3zlYL3DMurder and Mayhem on Chicago's South Side by Troy Taylorhttps://amzn.to/3BeIjmg (paperback)https://amzn.to/3kkBVmK (FREE with Kindle Unlimited)Join Kindle Unlimited here: https://amzn.to/2WsP1GHSecond City Sinners: True Crime From Historic Chicago's Deadly Streets  by Jon Seidelhttps://amzn.to/3g5n1jsUnknown Chicago Tales by John R. Schmidthttps://amzn.to/3x6GgPhSo many Chicago movies and documentaries can been found here:https://amzn.to/38F6hehChicago History Podcast Clothing, Mugs, Totes, & More (your purchase helps support the podcast):https://www.teepublic.com/user/chicago-history-podcasthttps://chicago-history-podcast.creator-spring.com/Chicago History Podcast (chicagohistorypod AT gmail.com):https://www.chicagohistorypod.comArt by the amazing John K. Schneider (angeleyesartjks AT gmail.com)Support the show

Metastatic Triple Negative Breast Cancer is one of the most challenging breast cancer subtypes to treat. Recurrence rates can be as high as 40%. This episode covers the role of immunotherapy and antibody-drug conjugates in the advanced space. Once again, targetable receptors are lacking but research is underway!Studies discussed in the episode:KEYNOTE 355ASCENTFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Hi Guys! We hope you enjoy our very first episode of DYGTOF- Pulse Check. This week, we are discussing new trailers, upcoming remakes/ releases, horror at the Oscars and Scream 7 casting announcements.Pulse Checks won't be our typical movie reviews, but instead us freely discussing various horror topics including interests, recent events, updates and announcements. But don't worry, these will not be replacing our movie reviews, we have plenty of those coming soon! Brought to you by your hosts, Ruth and DP.You can follow DP and find all of his movie ratings on his letterbox:https://letterboxd.com/maybetomorrow/ Please support us by following us on any (preferably all) of our social media platforms. It really means the world to us!  Instagram: https://www.instagram.com/didyougetthatonfilm/ Facebook: https://www.facebook.com/didyougetthatonfilm/ Youtube: https://www.youtube.com/@DidYouGetThatOnFilm Website: https://didyougetthatonfilm.buzzsprout.comArt by Sebastian Westbrook (@Spwestbrookart on Instagram and Facebook)

It's been an "Olympic" ride to get here, and this is our penultimate breast cancer episode! Today, we talk about the BRCA mutations and how they impact both breast cancer and outcomes using targeted therapy. BRCA is a tumour suppressor gene.Today, we explore olaparib and its role in the adjuvant and metastatic setting for breast cancer.Studies discussed in the episode:OLYMPIAOLYMPIADFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do. Hosted on Acast. See acast.com/privacy for more information.

Metastatic Hormone Receptor-Positive Breast Cancer truly represents the frontier of Medical Oncology, with life expectancy creeping up to and beyond five years. This week, we discuss Monaleesa-2 (Ribociclib), Paloma-2 (Palbociclib) and, of course, highlight the importance of Monarch-3 (Abemaciclib). The great CDK debate continues, and while the phase three trials have a clear winner, it's important to discuss the benefits and cons of each.Studies discussed in the episode:MONALEESA-2PALOMA-2MONARCH-3 (Mention)For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do. Hosted on Acast. See acast.com/privacy for more information.

Early Triple Negative Breast Cancer remains an aggressive variant of all breast cancers, affecting those under 40 more and has a higher propensity for being in those with BRCA1/2 mutations. It represents about 15% of all breast cancers.This week, we explore the benefit of immunotherapy (pembrolizumab), looking at improved complete pathological response as a surrogate marker for OS and the role of capecitabine in the adjuvant setting.Studies discussed in the episode:CREATE-XKEYNOTE-522For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do. Hosted on Acast. See acast.com/privacy for more information.

Our second SABCS (San Antonio Breast Cancer Symposium) episode covers everything (else) you need to know from 2024. In this episode, we dive into the role of trastuzumab deruxtecan in HR +ve, HER2 low cancers, perioperative atezolizumab in tnbc, the use of a novel ADC (SHR-A1811) and the role of tumour mutational burden in triple-negative cancer.Studies discussed in the episode:DESTINY-Breast06Neoadj atezoFASCINATE-NKEYNOTE-522For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do. Hosted on Acast. See acast.com/privacy for more information.

Welcome back to Oncology for the Inquisitive Mind, where we head back to late 2024 and cover some pivotal trials and ideas from the San Antonio Breast Cancer Conference 2024.This episode broadly covers hormone receptor-positive breast cancer and looks at another CDK comparison (real-world data). While the idea is not new, the potential implications from well-gathered "phase 4" data is a curious discussion point. Other topics include the ESR1 mutation and Imlunestrant, Patritumab Deruxtecan in hormone receptor-positive disease and the role of CTDNA in tumour burden and recurrence in early breast cancerStudies discussed in the episode:SOLTI-VALENTINEEMBER 3ctDNA in EBCCDK ComparisonFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do. Hosted on Acast. See acast.com/privacy for more information.

This Christmas, Art the clown gives new meaning to the moniker ‘Bad Santa.'Join us as we discuss Damien Leone's 2024 Xmas slasher, ‘Terrifier 3.'Brought to you by your hosts, Ruth and DP.Please support us by following us on any (preferably all) of our social media platforms. It really means the world to us!Instagram:https://www.instagram.com/didyougetthatonfilm/ Facebook: https://www.facebook.com/didyougetthatonfilm/ Youtube: https://www.youtube.com/@DidYouGetThatOnFilm Website: https://didyougetthatonfilm.buzzsprout.comArt by Sebastian Westbrook (@Spwestbrookart on Instagram and Facebook)

Before immunotherapy, targeted chemotherapy (ADCs) and precision oncology, there was endocrine therapy, the forefather (or mother) of effective treatment to reduce breast cancer recurrence as well as delay disease progression. This episode dives into a past of phenomenal improvement in the adjuvant breast cancer space. How long should one take endocrine therapy? We cover all the facts you need to know as a clinician or if you are curious from a patient/learning perspective.Studies discussed in the episode:EBCTCG Group - 2011 + 2015ATLAS trialBIG 198 trialPatient-level meta-analysis of the randomised trialsIDEAL studyFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do. Hosted on Acast. See acast.com/privacy for more information.

HER2 Breast Cancer is complicated, and this week, we explore those with residual disease post neoadjuvant therapy (KATHERINE) and the idea of de-escalation in a subpopulation of HER2-positive breast cancer patients (PERSEPHONE). The advent of a new class of drugs leads to excitement, unanswered questions and boundless opportunities. With ADC (antibody-drug conjugates) making their mark on traditional chemotherapy, the landscape of everything we treat is slowly changing. Studies discussed in the episode:KATHERINEPERSEPHONEFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do. Hosted on Acast. See acast.com/privacy for more information.

Human epidermal growth factor receptor 2 (HER2) is overexpressed in multiple cancers, including breast, gastric, colorectal, and epithelial ovarian cancers. However, this receptor's complexity doesn't stop there. It has multiple subdomains and various responses to drugs, and the complete picture is yet to be understood.This week, we explore the original wonder drug (Trastuzumab) in the early breast cancer space and its compatriot, Pertuzumab. Josh highlights the association between pathological complete responses and event-free survival/overall survival, while Michael looks at Neosphere and picks apart the data to help understand where this drug is most beneficial.Studies discussed in the episode:NEOSPHEREGEPARQUINTONOAH TRIALFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do. Hosted on Acast. See acast.com/privacy for more information.

Early Breast Cancer had one of its defining moments in the 1990s, when five years of adjuvant tamoxifen reduced the recurrence risk of invasive breast cancer by 49%! These days, those types of improvements are much harder to substantiate with the effect treatments currently on the market, but there is promise. This week, on our Back to Basics episode, Michael and Josh look at the role of abemaciclib and ribociclib in the adjuvant setting in patients with high-risk early breast cancer. Both of these drugs are CDK4/6 inhibitors and have been shows to be efficacious in the metastatic hormone receptor positive status breast cancer space.This week we explore MONARCH-E and NATALEE and highlight the data and how it could impact CKD's role in this emerging landscape.Studies discussed in the episode:MONARCH-ENATALEEFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do. Hosted on Acast. See acast.com/privacy for more information.

Breast Cancer is complex, as are the treatment options that clinicians and patients must traverse. Stage III breast cancer has up to a 57% chance of recurring up to 20 years after diagnosis. Josh and Michael look at one of the practice-changing papers that tried to address how to manage high-risk patients. This study is called Soft and Text. It asked if adding ovarian suppression to aromatase inhibitors was better than ovarian suppression with selective estrogen receptor modulators (SERMs) to reduce the risk of recurrence in premenopausal women.Studies discussed in the episode:SOFT and TEXTFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do. Hosted on Acast. See acast.com/privacy for more information.

Happy Halloween 2024, everybody!! Have you been wondering what Art the Clown was up to before sawing women in half? Look no further.Join us as we discuss Damien Leone's 2013 horror anthology film, ‘All Hallows' Eve.'Brought to you by your hosts, Ruth and DP.Please support us by following us on any (preferably all) of our social media platforms. It really means the world to us!Instagram:https://www.instagram.com/didyougetthatonfilm/ Facebook: https://www.facebook.com/didyougetthatonfilm/ Youtube: https://www.youtube.com/@DidYouGetThatOnFilm Website: https://didyougetthatonfilm.buzzsprout.comArt by Sebastian Westbrook (@Spwestbrookart on Instagram and Facebook)

Today is our 1 year anniversary!! We are really sorry for the delay you guys! Thank you for being so patient. We promise we are working on being more consistent with our episode releases!But this week, our grave stays empty!Join us as we discuss Danny Cannon's 1998 slasher sequel, ‘I Still Know What You Did Last Summer.'Brought to you by your hosts, Ruth and DP.Please support us by following us on any (preferably all) of our social media platforms. It really means the world to us!Instagram:https://www.instagram.com/didyougetthatonfilm/ Facebook: https://www.facebook.com/didyougetthatonfilm/ Youtube: https://www.youtube.com/@DidYouGetThatOnFilm Website: https://didyougetthatonfilm.buzzsprout.comArt by Sebastian Westbrook (@Spwestbrookart on Instagram and Facebook)

After a short hiatus, we are back!And this time, when we kill a man, we are making sure he is really dead.Join us as we discuss Jim Gillespie's 1997 teen-centric slasher, ‘I Know What You Did Last Summer.' What are you waiting for, huh??Brought to you by your hosts, Ruth and DP.Please support us by following us on any (preferably all) of our social media platforms. It really means the world to us!Instagram:https://www.instagram.com/didyougetthatonfilm/ Facebook: https://www.facebook.com/didyougetthatonfilm/ Youtube: https://www.youtube.com/@DidYouGetThatOnFilm Website: https://didyougetthatonfilm.buzzsprout.comArt by Sebastian Westbrook (@Spwestbrookart on Instagram and Facebook)

Hold on to those car keys because things are about to get frucked up!Join us as we discuss Jordan Peele's 2017 groundbreaking directorial debut, ‘Get Out.'Brought to you by your hosts, Ruth and DP.Please support us by following us on any (preferably all) of our social media platforms. It really means the world to us!Instagram:https://www.instagram.com/didyougetthatonfilm/ Facebook: https://www.facebook.com/didyougetthatonfilm/ Youtube: https://www.youtube.com/@DidYouGetThatOnFilm Website: https://didyougetthatonfilm.buzzsprout.comArt by Sebastian Westbrook (@Spwestbrookart on Instagram and Facebook)

Rusty nail or surrogate baby daddy? You decide.Join us as we discuss Michael Mohan's 2024 bloody nunsploitation smash hit, ‘Immaculate.'We would like to give a special shoutout to Dan for requesting this one. As mentioned in the episode, if you are interested in very cool original artwork, please consider following Dan's page @drawn_by_dan (instagram). It would mean a lot to us and to him! Brought to you by your hosts, Ruth and DP.Please support us by following us on any (preferably all) of our social media platforms. It really means the world to us!Instagram: https://www.instagram.com/didyougetthatonfilm/ Facebook: https://www.facebook.com/didyougetthatonfilm/ Youtube: https://www.youtube.com/@DidYouGetThatOnFilm Website: https://didyougetthatonfilm.buzzsprout.comArt by Sebastian Westbrook (@Spwestbrookart on Instagram and Facebook)

I want to play a game. Listen or die. Make your choice.Join us as we discuss James Wan's 2004 debut smash hit, ‘Saw.'This is the fourth and final episode in our listener request movie series. We are so excited to be covering movies recommended to us by some of our favorite listeners.We would like to give a special shoutout to DP's baby sister, Dondria for requesting this one.Brought to you by your hosts, Ruth and DP.Please support us by following us on any (preferably all) of our social media platforms. It really means the world to us!Instagram: https://www.instagram.com/didyougetthatonfilm/ Facebook: https://www.facebook.com/didyougetthatonfilm/ Youtube: https://www.youtube.com/@DidYouGetThatOnFilm Website: https://didyougetthatonfilm.buzzsprout.comArt by Sebastian Westbrook (@Spwestbrookart on Instagram and Facebook)

Matt, Heather and Nick are joined by actor Craig Lee Thomas to talk about his performance as the Spokesperson of Super Earth in Helldivers 2, their experiences playing the game with each other, and more! Follow us on Twitter and Instagram @getplayedpod. Music by Ben Prunty benpruntymusic.comArt by Duck Brigade duckbrigade.comCheck out our Anime watch-along podcast Get Anime'd and our complete Get Played, How Did This Get Played? and Premium DLC back catalogue only on patreon.com/getplayedJoin us on our Discord server here: https://discord.gg/getplayed Wanna leave us a voicemail? Call 616-2-PLAYED (616-275-2933) or write us an email at getplayedpod@gmail.com Advertise on Get Played via Gumball.fmSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Matt, Heather and Nick talk about Final Fantasy VII: Rebirth, Balatro and discuss the film Kingsglaive: Final Fantasy XV. Follow us on Twitter and Instagram @getplayedpod. Music by Ben Prunty benpruntymusic.comArt by Duck Brigade duckbrigade.com Check out our Anime watch-along podcast Get Anime'd and our complete Get Played, How Did This Get Played? and Premium DLC back catalogue only on patreon.com/getplayed Join us on our Discord server here: https://discord.gg/getplayed Wanna leave us a voicemail? Call 616-2-PLAYED (616-275-2933) or write us an email at getplayedpod@gmail.com Advertise on Get Played via Gumball.fmeeSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.